Position in CYTK
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$344,934
+$78,065 QoQ
Shares Held
4,049
0.0% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#332
of 477 holders
Holding Since
Jun 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SHELTON CAPITAL MANAGEMENT holds $30,019,192 across 14 Biotechnology names. CYTK ranks #10 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
29,423 | $14,615,286 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
11,459 | $7,145,144 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
14,556 | $4,381,792 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
14,598 | $516,623 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
1,967 | $473,987 | |
| 6 | EXEL |
Exelixis, Inc.
|
8,157 | $443,822 | |
| 7 | PRTA |
Prothena Corp Public Ltd Co
|
39,472 | $386,430 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
4,460 | $363,534 |
All Filings in CYTK
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $344,934 | 4,049 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $266,869 | 4,049 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $257,273 | 4,049 | Shares | Sole | 2026-02-17 | |
| 2024-09-30 | $210,936 | 3,995 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $216,449 | 3,995 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $293,971 | 4,193 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $388,311 | 4,651 | Shares | Sole | 2024-02-14 | |
| 2022-12-31 | $247,061 | 5,392 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $261,242 | 5,392 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $211,851 | 5,392 | Shares | Sole | 2022-08-11 | |
| No filing history on record for this holder in this stock. | ||||||